C4X Discovery raises £15mln to assist with partnership discussions
“Our key programmes continue to demonstrate progress and generate positive data"
Company
C4X Discovery Holdings PLC
LON:C4XD
C4X Discovery Holdings PLC is a pioneering drug discovery company combining scientific expertise with cutting-edge drug discovery technologies to efficiently deliver world leading medicines. The company has a highly valuable and differentiated approach to drug discovery through its enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. C4X Discovery's commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage drug discovery programmes ready for out-licensing to partners and it has two commercially partnered programmes with one candidate in clinical development.
96 stories · page 3 of 5
C4X Discovery makes significant progress; hails start of Indivior trial, joins coronavirus initiative
“We remain committed to deliver and drive novel small molecule drugs against challenging targets towards clinical development," said CEO Clive Dix
C4X Discovery CEO appointed to UK Vaccine Taskforce
The taskforce has been set up by the UK government’s chief scientific adviser, deputy chief medical officer, business secretary and health secretary to lead efforts to find and manufacture a coronavirus vaccine
C4X Discovery boosts working capital with oversubscribed placing
Funds from the share issue should provide C4X with at least twelve months working capital, assuming it gets its usual tax credits
C4X Discovery hails progress; exited first half in strong financial position
"We continue to progress our portfolio, with our inflammatory programmes generating significant advances,” said chief executive Clive Dix
C4X Discovery confident of its business strategy
"We are making great strides toward our goal of one day becoming the world's most productive drug discovery company," said Eva-Lotta Allan, C4X's chairperson.
C4X Discovery says clinical trials "in sight" for opioid addiction treatment
Indivior was licensed to develop and commercialise C4X's opioid addiction treatment, and it has now selected Altasciences to run early studies into its safety
C4X Discovery unveils plans for £6.5mln fundraising as licensing discussions continue
The drug developer is aiming to raise the funds through a combination of a placing, a subscription and an open offer
C4X Discovery “very confident” of delivering deals in the near future
In a business update it said it is in licensing discussions with potential partners for two of its early-stage drugs
C4X Discovery molecule gets US funding
The award will fund a phase I trial of Orexin-1 along with the toxicology and drug metabolism studies needed to start a phase II assessment
C4X Discovery hires industry heavyweight to lead drug discovery network
The mission of Robin Carr, who has worked with both GlaxoSmithKline and Astex, is to bring together small molecule drug discovery and development experts from across the globe.
Archive
Proactive news snapshot: Metal Tiger, Thor Mining, Berkeley Energia, Galantas Gold …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Creo Medical floats higher after first commercial orders for Speedboat
A look at the day's major movers, including China New Energy, Pressure Technologies, Remote Monitored Systems, Vela, 1pm, Carpetright, RedT, MOD Resources and Metal Tiger
C4X teams up with PhoreMost to look for potential Parkinson’s treatments
By combining their drug discovery and validation platforms, C4X and PhoreMost hope to find drug targets that can potentially treat Parkinson’s sufferers
Archive
Proactive news snapshot: Sirius Minerals, AFC Energy, Location Sciences …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Solid State sparks rally with bullish trading update
A look at some of the biggest risers and fallers in London on Tuesday
C4X Discovery sees significant interest in drug programme
It confirmed it has spoken to "multiple" potential partners for its NRF-2 activator
Archive
FTSE 100 closes in red as China manufacturing data sends chill
The UK's premier share index shed over 22 points at 7,418, while the FTSE 250 shed over 86 points at 19,824
Archive
Impressive first quarter performance needed from oil giant BP after recent share price rally
The Day Ahead also brings updates from the likes of blue-chip lender Standard Chartered, Premier Inn owner Whitbread and pubs group Greene King
Archive
Proactive news snapshot: Strategic Minerals, Kodal Minerals, e-Therapeutics, Ceres Power …
A glance at some of the day's highlights from the Proactive Investors newswire